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Abstract
Triple negative breast cancer (TNBC) defined as lacking expression of the estrogen receptor,
progesterone receptor and HER2, comprises approximately 15% of incident breast cancers and is
over-represented among those with metastatic disease. It is increasingly clear that TNBC is
heterogeneous and that there are several biologically distinct subtypes within TNBC, in particular
the basal-like subtype but also the claudin-low, among others. While the incidence of BRCA
mutations across all subsets of breast cancer is quite low (~5%), BRCA mutations are more
common among those with TNBC (~20%) and may have therapeutic implications. The general
principles guiding the use of chemotherapy and radiation therapy do not differ dramatically
between early stage TNBC and non-TNBC. There is a trend, however, to treat TNBC at a lower
stage with chemotherapy as this is the only way to systemically reduce recurrence risk. In the
metastatic setting, while cytotoxic chemotherapy is the mainstay of treatment for advanced TNBC,
there are many promising targeted therapies in development in both the preclinical and early phase
clinical trial settings. While the treatment of TNBC remains a challenge, coordinated efforts
between clinician/scientist partnerships providing a comprehensive understanding of TNBC
genomic, proteomic and other biologic processes may result in individualized therapy for TNBC
faster than other subtypes -- driven by both the heterogeneity we know exists within this clinical
entity and the intense need for improved treatment.
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Introduction: Overview and Scope of the Problem
The management of triple negative breast cancer (TNBC), a disease that affects
approximately 180,000 women world-wide, is challenging1. Clinically defined as lacking
expression of the estrogen receptor (ER), the progesterone receptor (PR) and expression of
HER2 by immunohistochemistry (IHC), TNBC comprised approximately 15% of incident
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breast cancers and is over-represented among those with metastatic disease2–4. TNBC is
usually high grade, more often an “interval” breast cancer (ie. diagnosed between screening
mammograms) and, when recurrent, preferentially relapses in visceral sites such as lungs,
liver and brain4–6. Given the higher rates of recurrence and lack of traditional targets (such
as ER and HER2), treating those with TNBC evokes anxiety on the part of both the patient
and provider. In this review article, we will address the unique biology of TNBC, followed
by a detailed discussion of state-of-the-art local and systemic treatments in the early stage
setting. We will then discuss approved cytotoxics to treat advanced TNBC and the many
emerging targeted agents in development to treat this aggressive disease.
Unique Biology of Triple Negative Breast Cancer
As above, TNBC is defined clinically as lack of ER, PR and HER2 expression by IHC (with
confirmation of HER2 status by fluorescence in-situ hybridization [FISH] if indeterminate
[2+] by IHC). As per the most recent ASCO/CAP guidelines, ER and PR negativity is
strictly defined as <1% expression, as opposed to older definitions allowing up to 1 –10%
“borderline” ER/PR expression7. Interestingly and in an analysis of > 1,700 breast tumors,
while the majority of TNBC’s (as strictly defined by IHC as <1% ER/PR expression) fall
into the basal-like subtype by gene expression analysis (207/283, 73%), borderline cases (n
= 48) were more commonly luminal (46%) or HER2-enriched (29%)8 Based on this
observation, it is recommended that clinical trials aimed at enrolling women patients with
TNBC/basal-like breast cancer should adhere to the ASCO/CAP guideline recommended
definition of ER/PR < 1% when developing inclusion/exclusion criteria.
While the basal-like breast cancer subtype has been associated with TNBC for nearly a
decade, newer subtypes within TNBC are emerging9,10. More recently, a novel molecular
subtype identified as Claudin-low has been characterized via gene expression of human
breast tumors, a panel of breast cancer cell lines, and mouse models of breast
cancer11_ENREF_11. Clinically, Claudin-low breast tumors are commonly ER, PR and
HER2 negative via immunohistochemistry, show a high frequency of metaplastic and
medullary differentiation, and an intermediate response to cytotoxic chemotherapy (between
that of Basal-like and Luminal breast tumors). Moreover, Claudin-low breast tumors have
been shown to exhibit stem-cell characteristics, low expression of cell-cell adhesion proteins
(i.e. Claudin 3, 4 and 7), high enrichment for epithelial-to-mesenchymal transition (EMT)
markers, and low luminal/epithelial differentiation.
A second group of investigators has further dissected the biology of TNBC, identifying 6
unique subsets of TNBC through gene expression analysis of over 500 breast tumors from
over 20 independent datasets12. This analysis classified TNBC into the following clusters: 2
basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a
mesenchymal stem–like (MSL), and a luminal androgen receptor (LAR) subtype.
Approximately 30 TNBC cell lines were then classified into each of the aforementioned
categories and pharmacologically inhibited to illustrate that classification may inform
therapeutic strategies. Results showed that the BL1 and BL2 subtypes, both with higher
expression of DNA damage response genes, responded to cisplatin. Response to PI3K/
mTOR (phosphatidylinositide 3-kinase/mammalian target of rapamycin) and SRC inhibition
was observed among the M and MSL subtypes, which are enriched for epithelial-
mesenchymal transition (EMT) and growth factor pathways. Finally, cell lines within the
LAR subtype were preferentially responsive to the androgen receptor (AR) antagonist,
bicalutamide – a concept that has borne out to a degree in the clinical arena13. Given the
apparent heterogeneity within TNBC, a “one-size-fits-all” approach is no longer appropriate
as we design clinical trials for patients with TNBC. Consideration of the distinct subsets
within TNBC will be paramount as we aim to improve outcomes for this aggressive disease.
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Association with BRCA mutations
In addition to advances in understanding the underlying biology of TNBC, several studies
have illustrated the association of TNBC with germline BRCA mutations. A recent
observational study aimed to determine the incidence of germline BRCA1 and BRCA2
mutations among 77 patients with TNBC14. BRCA mutations were detected in 19.5% of
patients: 15.6% BRCA1 and 3.9% BRCA2. Interestingly, in this cohort of patients,
outcomes were superior among BRCA mutation carriers as compared to wild-type patients,
including 5-yr recurrence free survival [RFS, 51.7% vs. 86.2%, p = 0.031] and 5-yr overall
survival [OS, 52.8% vs. 73.3%, p = 0.225]. Further confirming these findings, an integrated
molecular analysis of breast carcinomas in The Cancer Genome Atlas (TCGA), reports
~20% of Basal-like breast tumors harbored a BRCA1 or BRCA2 mutation, of which ~2/3
were germline and 1/3 somatic15. BRCA1 inactivation was found to be common among both
Basal-like breast cancer and serous ovarian cancer. This finding suggests shared driving
events for both diseases and that therapeutic approaches (i.e. use of platinums, taxanes and
inhibitors of PARP [Poly-ADP-Ribose Polymerase]) may be guided more by molecular
profile, and less by tissue of origin.
Therapeutic Options for Early Stage Triple Negative Breast Cancer
While the basic principles, including the surgical management, radiation therapy techniques,
and decisions regarding systemic therapies, are similar between stage I – III TNBC (as
defined by the TNM staging system) compared to endocrine and/or HER2+ counterparts,
there are some nuances specific to TNBC that should be considered. In addition, there have
been several provocative studies in the field of radiation therapy specific to patients with
TNBC that are worthy of review.
Local Therapy/Radiation Therapy
Given conflicting retrospective studies regarding whether women with TNBC are at a higher
risk of local recurrence following breast-conserving therapy (BCT) and whether they might
be better served by a modified radical mastectomy (MRM)16–18, it has become accepted that
either treatment paradigm is reasonable in the management of early stage TNBC. However,
recent studies suggested that early-stage TNBC patients may be at a higher risk for local
recurrence when treated with MRM alone, omitting post-mastectomy radiotherapy (RT) (i.e.
in T1-T2N0 patients lacking classic indications for post-mastectomy RT), which warrants
discussion.
In a large single institution retrospective review of 768 women with T1-T2N0 TNBC,
investigators from McGill University found a significant difference in locoregional
recurrence rates (LRR) between patients treated with BCT, MRM or MRM plus RT19. Five-
year LRR-free survival was 96% and 90% among BCT and MRM patients, respectively
(p<0.03), and MRM was the only independent prognostic factor associated with LRR (HR
2.5), suggesting that MRM alone may not be “enough” local therapy in these patients. A
prospective trial performed in Shanghai randomized 681 women with stage I-II TNBC after
MRM to chemotherapy +/− RT20. While not their primary endpoint(s), the investigators
found a statistically significant difference in relapse free survival (RFS) and overall survival
(OS), favoring the group who received both adjuvant chemotherapy and post-MRM RT.
Five-year RFS improved from 75% to 88% with the addition of RT, and adding RT
improved 5 year OS impressively from 79% to 90%. Although retrospective and thus
subject to unintended bias, these are intriguing but hypothesis-generating data, warranting
further study in a rigorous randomized controlled trial, but do not warrant a change in
clinical practice.
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Many TNBC patients receive neoadjuvant chemotherapy in the hopes of becoming BCT
candidates or as a means to assess in vivo response to systemic therapy. There has been a
growing discussion about whether or not to omit post-MRM RT in patients with significant
down-staging secondary to chemotherapy, or even to modify RT field design based on
response to chemotherapy. This issue is not unique to women with TNBC. Unfortunately,
there are no prospective data to support this practice. Retrospective data from MD Anderson
suggests that patients with residual nodal disease benefit from post-MRM RT, but those left
with stage I/II disease after chemotherapy do not derive such a benefit21,22, however
interpretation of these findings must acknowledge the limitations of subgroup analyses of
patients in whom the use of RT was left to the discretion of the physician, and the absence of
prospective or controlled studies. In the absence of prospective data, it remains standard of
care to irradiate the same fields (i.e chest wall, supraclavicular fossa with or without
irradiation of the internal mammary chain if cT3 or node positive) after neoadjuvant
chemotherapy as one would do if patients had up-front surgery.
Systemic Therapy – Neoadjuvant and Adjuvant Treatments and Ongoing Clinical Trials
The only opportunity for recurrence risk reduction to treat TNBC with curative intent is
systemic chemotherapy, as there are currently no approved targeted treatments, like
endocrine or HER2-directed therapy, to ameliorate baseline risk. As such and in compliance
with guidelines as put forth by the National Cancer Comprehensive Network
(www.NCCN.org), it is common and appropriate for oncologists to prescribe anthracycline/
taxane-based chemotherapy at a lower stage for TNBC compared with hormone receptor
positive counterparts. While use of a more aggressive regimen (i.e. anthracycline/taxane as
opposed to a taxane-based regimen) may be reasonable in many TNBC, it is also true that
“biology does not trump anatomy.” A small node-negative TNBC carries a low (15% or
less) 5-year risk of recurrence23 and a proportionally lower benefit of treatment. Using tools
such as AdjuvantOnLine, the mortality risk at 10 years for a T1a/bN0 tumors is <10%. An
observational study of over 1,000 T1a/bN0 TNBC found excellent prognosis, with 95%
remaining free of distant metastasis at 5 years and without a notable difference between
those that did and those that did not receive chemotherapy24. Taking this into account, a
reasonable algorithm for adjuvant chemotherapy in node-negative TNBC is to offer it if
tumor size is > 1cm (T1c) and otherwise medically-appropriate, a balanced discussion in
0.6–1.0 cm (T1b) tumors, and no adjuvant chemotherapy in breast tumors 0.5cm or less
(T1a). As with other subtypes of breast cancer, adjuvant anthracycline/taxane-based
chemotherapy is recommended in patients with lymph node positive disease (N1 or greater),
regardless of primary tumor size (Figure 1).
The principles that govern the decision to proceed with neoadjuvant versus adjuvant
chemotherapy are similar between TNBC and other subtypes of breast cancer. These
principles are largely driven by (1) resectability of the primary tumor and lymph nodes to
achieve negative margins and (2) the ability to cytoreduce a breast cancer to facilitate breast
conservation, as opposed to a mastectomy. Historically and as guided by the landmark study
National Surgical Adjuvant Breast and Bowel Project (NSABP) B-2725, chemotherapy
sequenced prior to (as opposed to after) surgery does not appear to improve survival.
However, response to chemotherapy, particularly achievement of pathologic complete
response (pCR), can help identify those patients with better prognosis. Basal-like/TNBC has
consistently been shown to be more sensitive to neoadjuvant chemotherapy (i.e. higher pCR
rates) than Luminal breast cancers. Collectively, however, TNBC patients experience poorer
overall outcomes as compared to other breast cancer subtypes. The poorer prognosis of
Basal-like/TNBC has been explained by a higher likelihood of relapse in those patients in
whom pCR was not achieved and has been termed the “triple negative paradox. 26,27
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Using pCR rates for patients with TNBC as an endpoint, investigators are evaluating
additional chemotherapies and targeted agents in the neoadjuvant setting. A trial of interest,
Cancer and Leukemia Group B, (CALGB) 40603 (NCT00861705), is evaluating the
addition of a platinum (i.e. carboplatin) and/or an anti-angiogenesis agent (i.e. bevacizumab)
to standard anthracycline/taxane-based neoadjuvant chemotherapy in the setting of locally-
advanced TNBC. Importantly, all patients in this trial are required to undergo dedicated
biopsies in order to identify predictive markers of response. Platinum agents have been an
area of investigation in TNBC based upon the hypothesis of augmented sensitivity to DNA-
damaging agents in dysfunctional BRCA. Although small studies have suggested high
clinical responses to cisplatin in germline BRCA mutation carriers28,29, whether this holds
true in sporadic TNBC is uncertain; prospective data await the results of CALGB 40603.
Results of neoadjuvant bevacizumab studies in TNBC have previously been mixed30,31, and
the addition of one year of bevacizumab to adjuvant chemotherapy in TNBC failed to
improve invasive disease-free survival in a recently-reported, large (n > 2,500 patients),
open-label, randomized, multi-national phase III trial32. Anticipated results of CALGB
40603 will continue to add our understanding of the role of bevacizumab, if any, in the
curative treatment of TNBC and to identify those patients who may benefit from these
approaches.
Another area of active research pertains to those with “residual disease” – specifically, the
group of patients with TNBC who do not achieve a pCR following neoadjuvant
chemotherapy – in an effort to improve outcome for those at greatest risk for local and/or
distant recurrence. While scientists are actively analyzing the molecular changes in residual
breast tumor following pre-operative cytotoxic therapy33, an ongoing randomized, phase III
trial is also evaluating the benefits of an intensive diet/exercise intervention or without
adjuvant metronomic chemotherapy (6 months of cyclophosphamide/methotrexate, CM)
plus bevacizumab (12 months) in patients with residual disease to determine if this strategy
will reduce recurrence among this high-risk group.
At this point, the choice of chemotherapy regimen does not differ between TNBC and non-
TNBC. Retrospective studies have suggested that much of the benefit of adjuvant
anthracyclines is in the HER2-overexpressing subset of tumors, however this finding is not
universal or definitive. More recently, molecular studies suggest that the HER2-enriched
molecular subtype derived the primary benefit of an anthracycline regimen (CEF,
cyclophosphamide, epirubicin, 5-fluoruracil) over classic CMF (cyclophosphamide,
methotrexate, 5-fluoruracil); in that retrospective analysis, the basal-like subtype appeared to
benefit equally from both regimens34. While intriguing, intrinsic subtyping for this purpose
is not yet clinically available, nor is it sufficiently validated for decision-making. While
TNBC behaves differently than other subtypes of breast cancer with higher local and distant
metastasis rates and earlier pattern of relapse, breast conservation and multimodality options
for care in the early breast cancer setting remain similar to other subtypes.
Advanced Triple Negative Breast Cancer
Principles of Systemic Therapy
In spite of great excitement in the recent past, with potential novel drugs like PARP
inhibitors and bevacizumab offering a “targeted” option in TNBC, we remain with multiple
cytotoxic choices, but no targeted therapy in the metastatic setting at this time. Conventional
treatment of metastatic TNBC begins with cytotoxic chemotherapy, of which there are ~14
single agents and ~8 doublets listed in the treatment of HER2-negative, recurrent or
metastatic breast cancer as per NCCN (www.NCCN.org). Choice of palliative cytotoxic
regimen is no different in TNBC than other subtypes, with options of poly-chemotherapy
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generally reserved for symptomatic or rapid visceral progression, and sequential single
agents for relatively asymptomatic, stage IV disease.
A recent randomized phase III study, CALGB 40502, confirms that weekly paclitaxel is the
optimal first-line regimen compared with the more modern microtubule-directed agents nab-
paclitaxel or ixabepilone, including in the TNBC subset35. A similar subset analysis in
TNBC of eribulin compared with capecitabine in the first to third line setting found no
difference between the two drugs overall, although the TNBC subset had improved
progression-free survival with eribulin compared with capecitabine. This subset analysis,
however, should be considered exploratory rather than definitive36. The decision of which
drug to use, in this case eribulin versus capecitabine, may reasonably be made on the basis
of their very different toxicity profiles. Many of our patients with advanced TNBC receive a
variety of cytotoxics while still medically well enough to do so; individualizing care and
selection of cytotoxic should be made on the basis of side effects, convenience, and personal
choice as opposed to strictly based on subtype.
Incorporation of a Platinum—As discussed in the treatment of early stage TNBC, the
question of how and when to sequence direct DNA-damaging agents in the treatment of
advanced TNBC remains unknown. Platinum drugs appear to have high single-agent activity
in BRCA1/2-associated cancers28,29, but platinum agents in sporadic TNBC demonstrate
reasonable, yet not excessively high response rates. As an example, the Translational Breast
Cancer Research Consortium (TBCRC) 009 trial found an approximately 30% response rate
to cis- or carboplatin in the first- or second-line treatment of advanced TNBC37; in the
control arm of BALI-1, first-line cisplatin alone produced responses in only 10% of
advanced TNBC patients38. These agents are appropriate to include in the armamentarium
of cytotoxic choices in TNBC but do not need to be preferentially used over other the many
other available agents with different mechanisms of action in sporadic, advanced TNBC.
Targeted Agents to Treat Advanced TNBC—Given the relative paucity of available
“targeted” agents, ongoing preclinical and clinical efforts are focused on the development of
more refined strategies to control advanced TNBC beyond that of cytotoxic chemotherapy
(Table 1). In the recently reported TCGA analysis, the most commonly mutated genes and
pathways in Basal-like/TNBC were the tumor suppressor gene TP53 (~80% mutated), loss
of RB1 (tumor suppressor gene) and BRCA1 (DNA repair gene) function, as well as
PIK3CA (~9%; as compared to approximately 30% – 49% in luminal A and B breast
tumors, respectively). Comprehensive protein analysis illustrated basal-like breast cancers to
have the highest relative PI3K pathway activation, likely via alternative mechanisms such as
loss of the negative regulators, PTEN and/or INPP4B. Other plausible drug targets identified
through this comprehensive analysis included FGFR1, FGFR2, IGFR1, KIT, MET,
PDGFRA, as well as angiogenesis and/or drugs that become activated under hypoxic
conditions. Large-scale, coordinated studies such as the TCGA will only continue to foster
our understanding of the complex biology underlying TNBC with the goal of translating
these findings into rationally-designed clinical trials, of which several historical trials and
strategies will be reviewed here.
Anti-angiogenic strategies—Anti-angiogenic strategies appeared promising based upon
preclinical data in TNBC models, however a pooled analysis, however, of three randomized
first-line metastatic studies of bevacizumab added to chemotherapy (E2100, AVADO, and
RIBBON-1) demonstrated improvement in progression-free survival (PFS), but no impact
upon overall survival in HER2-negative patients overall or in the TNBC subset39. Among
approximately 2,500 patients with HER2-negative metastatic breast cancer, median PFS
improved from 6.7 to 9.2 months (Hazard Ratio [HR] = 0.64, p<0.0001) in the bevacizumab
arms, and one-year survival rates were greater in the bevacizumab plus chemotherapy arm
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as compared to the control arms (81.6% versus 76.5%; respectively, p = 0.003). In spite of
these improvements, there was no difference in overall survival, which was 26.4 months in
the control arm and 26.7 months with the addition of bevacizumab. Based on lack of
survival benefit and toxicity, bevacizumab’s initial FDA accelerated approval in 2008 was
revoked in 2011; current use of bevaciuzmab in metastatic breast cancer is essentially
restricted to clinical trials. Biomarkers predictive of response to bevacizumab have been
difficult to identify; biomarker results from the neoadjuvant study CALBG 40603 are
anticipated in hopes of informing future studies in the metastatic setting to augment response
to anti-angiogenic strategies.
Inhibitors of Poly-ADP-Ribose Polymerase (PARP)—In those patients with
germline BRCA1 or BRCA2 mutations, PARP inhibition remains a promising avenue,
however this approach remains available only in clinical trials, and reports from small
studies have failed to demonstrate a similar outcome in sporadic TNBC. For example, a
phase II study of the PARP inhibitor olaparib revealed unconfirmed responses only in
BRCA1/2 carriers, with no responses among patients with sporadic TNBC40. A phase II
study of temozolomide with another PARP 1/2 inhibitor, velparib (ABT-888), enrolled 41
patients with metastatic breast cancer (~50% TNBC); response rate across the entire
population was 7%41, however an exploratory analysis revealed that responses were
essentially limited to BRCA1/2 carriers. In those 8 patients, the response rate (complete and
partial responses, CR/PR) was 37.5% with a clinical benefit rate (defined as CR, PR, and
stable disease [SD] > 16 weeks) of 62.5%. Progression free survival was 5.5 months for
BRCA mutation carriers and 1.8 months in non-carriers suggesting that the benefit from
PARP inhibition was largely derived from those harboring mutations in DNA repair, namely
through the BRCA pathway. Identifying non-BRCA associated TNBC tumors with similar
phenotype and DNA damage repair defect with potential to benefit from PARP inhibition,
with or without chemotherapy, remains a subject of intense and ongoing research.
Inhibition of Epithelial Growth Factor Receptor—While TNBC lacks ER and HER2
expression, expression of EGFR (epithelial growth factor receptor, HER1) has been
demonstrated among TNBC at both the gene and protein level2,6. Several studies have
evaluated the benefit of adding the EGFR-targeted monoclonal antibody, cetuximab, to
platinum-based chemotherapy to treat advanced TNBC with modest results. The TBCRC
001 study evaluated treatment with cetuximab as a single agent and/or combined with
carboplatin among 102 patients with advanced TNBC. Response rates for cetuximab as a
single agent, combined with carboplatin at progression following monotherapy, or with
cetuximab/carboplatin from the onset of treatment were 6%, 16% and 17%, respectively.42
While time to progression was short (2.1 months, 95% CI, 1.8 to 5.5 months), pre- and post-
therapy biopsies evaluating dynamic changes EGFR signaling provided further insight into
possible compensatory pathways that may have been responsible for the marginal benefit
observed from this novel drug combination. Dovetailing the results of TBCRC 001, the
BALI-1 study reported a doubling of response rates (RR) by combining cetuximab with
cisplatin as compared to cisplatin alone in TNBC (RR: 20% versus 10.3%, respectively)38.
Despite improvements in response, duration of response was quite short; progression free
survival was only 3.7 months following cetuximab/cisplatin versus 1.5 months following
cisplatin monotherapy. Although there was initial enthusiasm and strong preclinical
rationale for the incorporation of EGFR-based therapy into systemic therapy for advanced
TNBC, translation of this approach clinically has resulted in only modest improvements in
outcome, possibly due to heterogeneity of disease and compensatory alternate signaling in
the cancer cells. Biomarkers predictive of response to this targeted therapy or combinatorial
strategies may be needed to enrich for responders if this strategy is to be successful to treat
advanced TNBC.
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Inhibition of Androgen Receptor Signaling—The luminal androgen receptor (LAR)
subtype of TNBC is sensitive to androgen deprivation in preclinical studies12, making AR
signaling in ER-negative breast cancer an intriguing potential target. In the recent TBCRC
011 phase II trial, of > 450 hormone receptor-negative (primarily TNBC) screened, about
10% had AR expression, and single agent bicalutamide in these patients yielded clinical
benefit in 19%13. Continued study of AR pathway inhibition in advanced TNBC -- albeit the
small subset that may be driven by the AR pathway -- is certainly warranted as we move
toward the era of personalized medicine.
Inhibition of the PI3K, MEK, CHK and HDAC pathways - Preclinical—A
tremendous amount of research is ongoing in search of “targetable” pathways that may be
contributing to the aggressive biology of TNBC. As identified in TCGA, activation of the
PI3K phosphoinositide-3 kinase pathway (PI3K, either directly via PI3KCA mutations or
indirectly via PTEN and/or INPP4B loss) has been identified as important in TNBC/Basal-
like breast cancer15. Preclinically, inhibition of the PI3K pathway results in TNBC cell
growth arrest43; several small molecule inhibitors of the PI3K (and downstream mTOR
[mammalian target of rapamycin] pathway) are in development. Several studies, including
TCGA, have identified high rates of p53 (tumor suppressor gene) mutations in TNBC/Basal-
like breast cancer15. In the absence of p53 function, cells in need of DNA damage repair rely
on checkpoint kinase I (Chk1) to arrest the cell cycle and push potentially defective cells
toward apoptosis; p53-deficient mouse models of breast cancer are sensitive to Chk-1
inhibition.44,45. Chk-1 inhibitors have therefore become an attractive potential target for the
treatment of TNBC harboring p53 mutations. In addition, inhibition of MEK (mitogen-
activated protein–extracellular signal-regulated kinase), in combination with PI3K/mTOR
inhibition has shown activity in a TNBC/Claudin-low genetically engineered mouse model;
a “window” study of MEK inhibition (GSK1120212) is ongoing to evaluate dynamic
reprogramming of the kinome in patients with TNBC to further identify pathways of
resistance46,47._ENREF_46 (NCT01467310) Finally, epigenetic regulation of gene
expression has been a hot topic in TNBC for several years. An inhibitor of the HDAC
pathway (panobinostat) has been demonstrated to decrease cell growth in TNBC cell lines,
as well as tumorigenesis in vivo and may soon make its way into the clinic.48 This data is in
light of the randomized, phase II study, TBCRC 008, where the addition of vorinostat to pre-
operative carboplatin and nab-paclitaxel did not appear to improve pCR rates in a TNBC,
otherwise unselected, group of n = 62 patients (vorinostat arm pCR = 27.6%; placebo arm
pCR = 26.7%)49. Biomarkers predictive of those most likely to respond to HDAC inhibition
are needed.
Conclusions and Future Directions
In 2013, TNBC is well-recognized as a distinct subset of breast cancer with a unique
genomic background and characteristically aggressive clinical behavior in a relative sparse
landscape of available, standard-of-care, targeted therapies. Despite this recognition,
multimodality options for the care of TNBC in the early and advanced breast cancer settings
remain similar (with, of course, the absence of endocrine and HER2-directed strategies) to
other breast cancer subtypes. As we look ahead, we must ask ourselves, “What is the way
forward?” Based on emerging understanding of the complexity of TNBC, it may be that
clinician/scientist partnerships focused on comprehensive understanding of TNBC genomic,
proteomic and other biologic processes, will reorient us towards individualized therapy in
TNBC faster than other subtypes. This shift in focus will be driven by both the heterogeneity
we now know exists within TNBC and the intense need for improved treatment.
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1. Triple negative breast cancer (TNBC) lacks expression of the estrogen and
progesterone receptors and HER2 by clinical assays.
2. While more commonly associated with the basal-like subtype of breast cancer,
research assays have further dissected the biology of TNBC and have identified
six subtypes thus far.
3. The incidence of BRCA mutations is higher among patients with TNBC (~20%)
as compared to those with breast cancer across all subtypes (~5%).
4. Local and systemic therapy approaches to early stage TNBC should be similar
to that of non-TNBC; however endocrine and HER2-directed therapies are not
prescribed.
5. In the metastatic setting, the mainstay of systemic therapy to treat TNBC is
cytotoxic chemotherapy; targetable pathways are currently under investigation
in the preclinical setting and early phase clinical trials.
6. A coordinated effort between scientists and clinicians will be required to
develop novel therapies to treat TNBC most effectively.
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General Algorithm Guiding Adjuvant Chemotherapy Decisions in the treatment of Early
Stage Triple Negative Breast Cancer as adapted by www.NCCN.org, Version 1.2013,
Invasive Breast Cancer
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Table 1
Overview of Targeted Strategies in Advanced Triple Negative Breast Cancer
Therapeutic Target Phase of Study References
Angiogenesis Phase III 38
PARP inhibition Phase I/II 39,40
EGFR inhibition Phase II 41,37
Androgen Receptor signaling Phase II 13
PI3K inhibition Preclinical/Phase I 42
MEK inhibition Preclinical 46, 47
CHK inhibition Preclinical 43, 44
HDAC inhibition Preclinical/Phase II 48, 49
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